Oculis: eye drops with Dexamethasone/gamma-CD complex Phase 3 study concluded soon
Oculis’s most advanced product candidate, OCS-01, is currently in Phase 3 development and aims to be the first eye drop
Tag: dexamethasone
Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
The recently published patent application relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient such as dexamethasone and
Electrospun poly-ε-caprolactone fibers loaded with inclusion complex of sulfobutyl ether β-cyclodextrin with dexamethasone as potential drug release systems
Electrospun poly-ε-caprolactone (PCL) fibers (mats) loaded with inclusion complex of sulfobutyl ether β-cyclodextrin sodium salt (SB-β-CD) with dexamethasone (Dex) were
The effect of mucoadhesive polymers on ocular permeation of thermoresponsive in situ gel containing dexamethasone–cyclodextrin complex
The main aim of this study was to improve the solubility of dexamethason (DXM) with a CD derivative and increase
Dual-Sensitive CD-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis
In view of the overproduction of ROS and overexpression of cationic proteins in the inflammatory colon, the designed nanosystem was
Synthesis and Inclusion Properties of a β-Cyclodextrin Heptaphosphoramidate
The Canadian team reported a novel per-6-substituted β-cyclodextrin (4) featuring seven phosphoramidate moieties as an innovative host for inclusion. This
Novel dexamethasone formulation shows efficacy and safety with once-daily use
Eric D. Donnenfeld, a consultant to Oculis reported for Ophthalmology Times on the results of a phase 2 trial: dexamethasone
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced
Amgen’s Kyprolis, J&J’s Darzalex team up on myeloma survival win
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data